Episode 819: Cardiol Therapeutics ($CRDL): A New Approach to Treating Inflammation in Heart Disease

from Stocks To Watch · host Global One Media Pte. Ltd.

This interview is disseminated on behalf of Cardiol Therapeutics Inc.In this episode of Stocks to Watch, we sit down with David Elsley, President and CEO of Cardiol Therapeutics (NASDAQ: CRDL | TSX: CRDL), to discuss the company's late-stage clinical development program targeting inflammation-driven heart conditions, including recurrent pericarditis and acute myocarditis.Learn more: https://www.cardiolrx.comWatch the full YouTube interview here: https://youtu.be/NXkzgfWHQnAAnd follow us to stay updated: https://www.youtube.com/GlobalOneMedia

Episode metadata supplied by the publisher feed · Published May 19, 2026

Embed this episode

Attribution link and audio player

Ready to play

Episode 819: Cardiol Therapeutics ($CRDL): A New Approach to Treating Inflammation in Heart Disease

0:00 14:14

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Stocks To Watch?

This episode is 14 minutes long.

When was this Stocks To Watch episode published?

This episode was published on May 19, 2026.

Can I download this Stocks To Watch episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!